Spondyloarthritis & psoriatic arthritis
Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
Authors' conclusion
In biologic-naïve patients with active PsA, guselkumab provided early and durable improvements in key GRAPPA-recognised domains through 2 years, with substantial proportions achieving important treatment targets.
Study context
- Population
- Biologic/JAKi-naïve participants with active psoriatic arthritis (PsA) (≥5 swollen/≥5 tender joints, CRP ≥0.6 mg/dL)442/493 guselkumab-randomised completed W100
- Comparison
- Guselkumab every 4 weeks or every 8 weeks vs placebo with crossover to guselkumab
- Primary endpoint
- Long-term guselkumab effectiveness across Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-recognised PsA domains/related conditions
- Follow-up
- W100
Methodological detailsdouble-blind, placebo-controlled, placebo crossover to guselkumab
- Double-blind
- Placebo-controlled
- Placebo crossover to guselkumab
Primary result
As reported in the abstract
Response rates of therapeutic targets
| Outcome | Q4W | Q8W |
|---|---|---|
| DAPSA LDA | 62% | 59% |
| Enthesitis resolution | 61% | 70% |
| Dactylitis resolution | 72% | 83% |
| PASI 100 | 59% | 53% |
| PASDAS LDA | 51% | 49% |
| MDA | 38% | 40% |
Safety
Inflammatory bowel disease (IBD) among guselkumab-randomised patients · W112
- No cases of IBD
Uveitis among guselkumab-randomised patients · W112
- Cases of uveitis
- 1
Original publication
Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study. RMD Open. Published 26 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →